What a New International Expert Consensus Says About Eating on a GLP-1

If you are on a GLP-1, or coaching someone who is, here is the headline: a new international expert consensus says the drug was never supposed to be the whole plan. A panel of 15 physicians, researchers, and dietitians spent two rounds of formal review producing 52 statements on what nutrition and lifestyle support should look like at every stage of GLP-1 treatment, not just the injection itself, and it is the first document of its kind to do that (Sievenpiper et al., Obesity Pillars, 2026).

What is this consensus, and why does it matter?

Liraglutide, semaglutide, and tirzepatide have changed what is possible for weight loss, but the medications alone do not solve gastrointestinal side effects, nutrient gaps, or what happens to the body once someone stops. An international multidisciplinary panel, physicians, clinical researchers, and dietitians from multiple countries, used a two-round modified Delphi process (a structured way of building expert agreement through repeated, anonymous rounds of review) to work through those gaps. The result was 52 consensus statements, organized into seven practical modules: nutrition, physical activity, care before starting therapy, management during active weight loss, weight maintenance, gastrointestinal side-effect management, and what to do if therapy is discontinued (Sievenpiper et al., Obesity Pillars, 2026).

That full-arc structure is the news here. Plenty of guidance exists for managing GLP-1 side effects in the moment. What has been missing is a single, expert-agreed framework that treats nutrition and lifestyle support as continuous, before the first dose through life after the last one, rather than a series of disconnected tips.

The panel’s core position is stated plainly: these medications work best embedded in structured, individualized nutrition and lifestyle care, not used on their own. That is the same stance behind every plate of food a coach builds around a GLP-1, and it is worth saying out loud, because it is easy to assume the injection is doing all the work.

What changes before you even start?

The consensus treats the pre-treatment window as its own phase with its own supportive care, not a footnote before the “real” work of titration begins. The logic is straightforward: appetite is about to drop, sometimes sharply, so habits and a baseline nutritional picture are easier to establish before that happens than to build from scratch once eating gets harder. This is the same reason a coach front-loads structure, protein-forward meals, a hydration habit, a rough sense of a person’s typical plate, before a medication changes what “typical” even means.

What does the consensus say about protein during active weight loss?

This is where the panel gets specific, and it lines up with what the trial data has been showing for a while: a meaningful share of GLP-1 weight loss can be lean mass, not just fat (see the STEP 1 and SURMOUNT-1 body-composition substudies). During the rapid weight loss phase, the panel recommends protein intake of roughly 1.2 to 1.5 grams per kilogram of actual body weight per day, or about 25 to 30 percent of total calories on a 1600-calorie pattern, combined with continued physical activity, specifically flagging older adults and anyone at elevated risk of sarcopenia as needing extra attention here (Sievenpiper et al., Obesity Pillars, 2026).

That range sits close to the 1.2 to 1.6 g/kg target from the 2025 joint advisory on GLP-1 nutrition from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (Mozaffarian et al., American Journal of Clinical Nutrition, 2025). Two separate expert panels landing in roughly the same place is exactly the kind of convergence that should change how you eat on a GLP-1, not just how much.

The panel does not stop at a gram target. It also calls for that protein to be spread evenly across meals, paired with structured resistance training, not just cardio, to preserve lean mass. That is a harder ask when a GLP-1 has cut how much food fits into a day, which is exactly why sequencing (protein first, before anything else on the plate) matters more here than it would on a normal appetite. We wrote about the specific protein math and timing that makes this realistic when appetite is working against you.

What does the consensus say about GI symptoms?

Nausea, constipation, and other GI side effects get their own dedicated module in the consensus, a signal that the panel treats symptom management as core supportive care, not a side note to push through quietly. The panel’s inclusion of GI management alongside nutrition and activity reinforces a point we have made before: side-effect eating is a sequencing problem, not a matter of gritting your teeth through a normal-sized plate. For the specific food and fluid strategies that hold up against nausea and constipation in the early weeks, we cover that in detail here, and the guidance to always loop in your prescriber before adding anything like a laxative stands.

What about maintenance, once weight loss levels off?

Maintenance gets its own module too, distinct from the active weight loss phase. That distinction matters clinically: what a body needs while it is actively losing weight (a higher protein target, close attention to lean mass) is not identical to what it needs once weight has stabilized on the medication. The consensus frames maintenance as a phase requiring its own supportive nutrition plan, not simply “keep doing what you were doing,” which is consistent with how coaching should shift once the scale stops moving in one direction: from active-loss structure toward sustainable, repeatable habits a person can hold indefinitely.

What happens if someone stops the medication?

Discontinuation is the seventh module, and giving it a dedicated place in the consensus is itself notable. A lot of GLP-1 guidance stops at “how to lose the weight” and treats what happens after stopping as an afterthought. This panel does not. It formalizes that eating and activity structure need to be in place to carry appetite regulation once the drug’s effect steps back, since that is the mechanism the medication was providing. Whether and how to taper is a conversation for your prescriber, never a blog post, but the nutrition side of that transition, protein-forward plates, planned meals, consistent check-ins, is exactly what we have written about for keeping weight off after stopping a GLP-1.

The bigger picture

Read across all seven modules, the message is consistent: a GLP-1 is not a stand-alone intervention with nutrition as an optional add-on. It is a tool that performs better, and is easier to live with, inside structured, individualized support at every phase. That validates something worth saying plainly: coaching through a GLP-1, protein-first plates, phase-aware structure, symptom-aware adjustments, and a plan for what comes after, is not a nice extra. It is what an international panel of experts just said the evidence supports.

That is the same approach a coaching layer built around your actual week should be doing already: adjusting the plate math as your phase, appetite, and symptoms change, not handing you one static plan for the entire journey.